Zacks.com on MSN1d
Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great ChoiceMomentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell ...
Scotiabank raised the firm’s price target on Arcellx (ACLX) to $133 from $82 and keeps an Outperform rating on the shares. The firm adjusted its model following “highly compelling results” reported ...
Arcellx (NASDAQ:ACLX) announced an update for its Phase 3 iMMagine-3 study and plans to present Phase 1 and 2 data for its ...
Zacks.com on MSN7d
Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar?Arcellx (ACLX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Arcellx (NASDAQ:ACLX – Free Report) had its price target raised by Piper Sandler from $91.00 to $115.00 in a report issued ...
Does Arcellx, Inc. (ACLX) have what it takes to be a top stock pick for momentum investors? Let's find out. Arcellx ( NASDAQ:ACLX ) Third Quarter 2024 Results Key Financial Results Revenue ...
Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...
BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.
It’s an exciting time at Arcellx! We are preparing for the commercial launch of anito-cel as there remains an unmet need for a therapy that physicians can use across a broad patient population.” ...
Truist Financial analyst Asthika Goonewardene reiterated a Buy rating on Arcellx Inc (ACLX – Research Report) today and set a price target of $136.00. The company’s shares closed yesterday at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback